Pay in 4 interest-free payments of $6.32 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
We offer a range of options, including hydration for athletic recovery, immune support, hangover relief, and general wellness
Reduction in major cardiovascular events (SELECT trial, semaglutide) Reduced risk of progressing from prediabetes to type 2 diabetes (Tirzepatide, 3yr trial) Weight reduction significantly improves sleep apnea severity confirmed in multiple GLP-1 trials Emerging ADA 2026 data on GLP-1 anti-inflammatory effects and osteoarthritis improvement Improved basal metabolic rate and energy utilisation, especially with tirzepatides GIP pathway We believe cost transparency is part of quality care
Bifidobacterium bifidum CCFM1359 alleviates intestinal motility disorders through the BDNF-TrkB pathway
BPC-157 is dosed in micrograms (typically 250500 mcg per injection), so each 5 mg/5 ml vial covers many more individual doses than a semaglutide vial of the same volume
doi: 10.1007/s00210-010-0559-9 47 MirabelliMChiefariEPuccioLFotiDPBrunettiA
Below is a curated list of key papers and reviews supporting low-dose GLP-1s for autoimmune and inflammatory conditions : Review of the preclinical and clinical evidence demonstrating anti-inflammatory actions of GLP-1 across organ systems, independent of weight loss Single dose of semaglutide has anti-inflammatory effects that protects the body from infection-induced inflammation, dependent on binding brain GLP-1 receptors GLP-1 receptors present on multiple different types of immune cells and has been shown to induce an anti-inflammatory profile Anti-inflammatory effects of GLP-1 dependent on reprogramming immune cells to anti-inflammatory profile and are independent of weight loss In trials in obese individuals with knee osteoarthritis, early improvements in osteoarthritis symptoms are observed in early weeks while patients are still on microdoses of semaglutide Low semaglutide exposure (blood levels) drive anti-inflammatory benefits HIV patients titrated up to 1 mg of semaglutide demonstrate reduction in pro-inflammatory factors, patients spent 25% of trial on microdoses Review of anti-inflammatory effects of GLP-1 in various preclinical and clinical trials, some using equivalent to low doses Note: The above statements have not been evaluated by the Food and Drug Administration
